Category: Newsletters

Blue Horseshoe Stocks: FRO, OPK, WLGC & More

Frontline, Ltd. FRO

At the beginning of this month when we first began looking at FRO, the stock was trading at a low of 1.33. It took barely a week for the stock to start inching its way up, and it has continued to do so up to the present.

By the time we re-flagged it in Friday’s morning report, it had already cracked the $2.00-mark, and we did mention that the level of momentum was primed to allow for further opportunities.

This morning FRO continues to push the envelope, setting a new high in premarket trading action. This morning’s top figure of 2.64 puts us just slightly short of double-bagger status, having shown us an increase of 98% from the lows we observed the week before last.

It can be argued that the bolstering of activity seen on FRO (and other shipping plays) is due to the continuing fall of oil prices which translates to savings at the pump.

Opko Health, Inc. OPK

OPK is catching our attention in the premarket as well, as a result of an agreement announced this morning with pharma-giant Pfizer to develop and commercialize one of Opko’s highly promising products which combats Growth Hormone deficiency. Peruse the following PR to find out more; the development certainly lands OPK a spot on our watchlist to kick off the week.

In instances like these where a play is sent through the roof on substantial news, we look for the resulting profit-taking to pull the stock back, where we wait to take advantage of a possible dip-and-rip scenario.

OPKO Health, Inc. (OPK) and Pfizer Inc. (PFE) announced today that they have entered into a worldwide agreement for the development and commercialization of OPKO’s long-acting hGH-CTP for the treatment of growth hormone deficiency (GHD)… hGH-CTP has the potential to reduce the required dosing frequency of human growth hormone to a single weekly injection from the current standard of one injection per day. >> FULL PR

WordLogic Corp. WLGC

Speaking of significant news, WLGC forces its way into our vernacular this morning on the heels of the announcement that the company will be teaming up with energy-leviathan General Electric (GE) in order to “monetize specific patented intellectual property in General Electric’s portfolio.”

With such a high-profile bedfellow, WLGC will instantly gain new recognition, and it will be very interesting to see how that translates to the chart.

Notable Gainers from Friday’s Extended Watchlist

Oncothyreon, Inc. ONTY – Range: 1.69-2.05   Gain: 21%

Organovo Holdings, Inc. ONVO – Range: 5.82-6.50  Gain: 11%

Extended Watchlist:
TLM, SN, BLRX, KEG, HGSH, CPST

Blue Horseshoe Stocks: ODP Update, FRO & More

Frontline, Ltd. FRO

The last time we mentioned FRO was early this month, at which time the stock was trading at a low of 1.33. It has been ramping its way up over the past few sessions, making higher highs and higher lows, and we wanted to flag it once again this morning as it is trading up significantly in the premarket.

This morning’s high of 2.15 represents an increase of 61% over the 1.33-low that we observed as recently as Monday. With the heavy early-morning momentum we’re seeing we’ll want to follow along with this play closely today and into next week.


Talisman Energy, Inc. TLM

We’ll keep an eye on TLM today as well based on some heavy premarket activity and the fact that the stock is coming up off of its 52-week lows. We’ve noticed a break on the chart due to a gapdown from around 5.60 to 4.80, and with the stock currently trading in the 4.40’s, we should be on the lookout for it to possibly make a run at filling that gap.

ChemoCentryx, Inc. CCXI

Also popping up on our morning scan is CCXI, which is currently trading feverishly in the premarket on the heels of a PR early this morning regarding positive top line results on one of its products currently in testing.

With the stock up over 100% in early trading, we’re going to be on the lookout for massive profit-taking to potentially drive the price back down where it may set us up to take advantage of a dip-and-rip opportunity.

MOUNTAIN VIEW, Calif., Dec. 12, 2014 (GLOBE NEWSWIRE) — ChemoCentryx, Inc., (CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, today announced positive top-line 52-week data from its Phase II clinical trial in diabetic nephropathy with CCX140, an inhibitor of the chemokine receptor known as CCR2. >> FULL PR

Office Depot, Inc. ODP

ODP was a good call for yesterday’s session, as it made a solid 8% move on news that a large activist investor took up a significant position in Office Depot while raising its existing stake in Staple stock to 10% total ownership. It is fueling speculation that there could be pressure for a merger between the two, so this is definitely a story we’ll continuously track going forward.

Extended Watchlist:
ONVO, ONTY, DENN, FCEL, UBIQ

Blue Horseshoe Stocks: ABIO Recap & More

ARCA BioPharma, Inc. ABIO

Our top performer from yesterday’s report was most assuredly ABIO. We tagged this play after noticing that it had announced being granted orphan drug status by the FDA for “rNAPc2” as a potential treatment of viral hemorrhagic fever post-exposure to the Ebola virus.

Fresh FDA-related plays can often provide a healthy move to take advantage of, and that’s just what we got from ABIO, The stock traded in a range from .82-1.03, an intraday increase of 25% on nearly ten times the 3-month average volume.

Our long-time readers might recall our coverage of this stock last year in December, which sort of got lost in the shuffle that was the hysteria created by the “Green Rush”. We tracked the stock from the low 1.40’s to over 2.20 over a period of a few weeks, so it will be interesting to see if history continues to repeat itself with ABIO, especially with the stock coming off of it 52-week low on Tuesday.

CYREN Ltd. CYRN

We also wanted to acknowledge the early morning move made by another of the stocks we mentioned in yesterday’s newsletter, CYRN. It bolted out of the gate, quickly running from 2.22 to 2.67, a 20% spike within the first 15 minutes of the session.

The stock got hammered into the close quite a bit, so we’ll be open to the possibility of seeing some bounce action, provided it can hold support at or above the 50DMA of 1.75.

Office Depot, Inc. ODP

ODP is in the midst of making a big move on the heels of large activist investor Starboard Value taking up a position which equates to 6% of ODP’s total shares. It also upped its stake in Staples to 10% fueling speculation that it could create pressure for the two office supply giants to merge. It will definitely be a story that we’ll be interested to follow moving forward.

Extended Watchlist:
GPT, RGDX, CYTX, DRD